For this patient with moderate-volume unfavorable intermediate-risk disease,[@bib1] we would generally treat with 6 months of androgen deprivation therapy (ADT). Studies of dose-escalated therapy (GETUG-14, EORTC 22991) thus far have not found that dose escalation can substitute for ADT. His cardiac history is not severe enough to make us concerned that the survival benefit of ADT would be lost. While waiting for the COVID-19 peak in Massachusetts to pass, we delayed radiation initiations by giving 5 to 6 months of the ADT course neoadjuvantly, per TROG 96.01.[@bib2] Traditionally, we have used 44 fractions of 1.8 Gy, but during the pandemic we have more frequently treated with moderate hypofractionation (60 Gy in 20 fractions).

For high-risk disease, we would offer ADT for 2 years and 28 fractions of intensity modulated radiation therapy plus a brachytherapy boost per ASCENDE-RT.[@bib3] If procedures were being limited due to a COVID-19 surge we would use 60 Gy in 20 fractions. We do not typically treat the pelvic lymph nodes prophylactically for localized high-risk disease except for young patients at the highest end of the risk spectrum, and we await the results of RTOG 09-24. We would not offer stereotactic body radiation therapy for high-risk disease off trial, but a future NRG trial may be testing stereotactic body radiation therapy for high risk.

Without symptoms or potential exposures, we would not routinely test for SARS-CoV-2, but we would screen daily and test as needed. The pandemic has led us toward more use of moderate hypofractionation, but we continue to favor combination therapy per ASCENDE-RT for high-risk or higher volume unfavorable intermediate-risk patients.
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What would you do? Continue the discussion on Twitter at [\#gyzone](http://ctt.ec/pi683){#interref0010rdf}, and take the poll at [www.redjournal.org/poll](http://www.redjournal.org/poll){#interref0010}.
